Amgen Inc. $AMGN Position Boosted by Prestige Wealth Management Group LLC

Prestige Wealth Management Group LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 120.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,213 shares of the medical research company’s stock after buying an additional 1,758 shares during the quarter. Prestige Wealth Management Group LLC’s holdings in Amgen were worth $1,052,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in AMGN. Anfield Capital Management LLC lifted its position in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the period. Dogwood Wealth Management LLC lifted its position in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the period. Board of the Pension Protection Fund acquired a new stake in Amgen in the fourth quarter worth approximately $26,000. Manning & Napier Advisors LLC lifted its position in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new stake in Amgen in the fourth quarter worth approximately $33,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission approval for Imdelltra, a regulatory win that could expand its cancer-treatment revenue opportunity in Europe. EC approval for Amgen’s Imdylltra
• Positive Sentiment: Amgen said it will present new data across rare autoimmune and inflammatory diseases at EULAR 2026, with updates supporting UPLIZNA and TAVNEOS, which may reinforce confidence in its specialty-drug growth. Amgen to Present New Data Across Rare Autoimmune and Inflammatory Diseases at EULAR 2026
• Positive Sentiment: Amgen announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference, which could keep investor focus on its strategy and pipeline progress. Amgen to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
• Neutral Sentiment: Amgen’s appearance at the Jefferies Global Healthcare Conference is keeping the stock in the spotlight, but the transcript itself does not add a clear new catalyst. Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Amgen is also getting some broader attention from commentary on AI adoption in biotech and analyst notes on healthcare names, but these items appear more informational than stock-moving. The CEO who loves AI autodidacts — and desperately needs his experts Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Thermo Fisher (TMO)

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Argus cut their target price on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Daiwa Securities Group cut their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Canaccord Genuity Group assumed coverage on Amgen in a research report on Monday, April 20th. They issued a “hold” rating and a $366.00 target price for the company. Finally, UBS Group upped their target price on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $355.19.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $345.60 on Friday. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The stock has a fifty day moving average of $341.44 and a 200-day moving average of $345.44. The company has a market capitalization of $186.52 billion, a PE ratio of 24.05, a price-to-earnings-growth ratio of 3.39 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the firm earned $4.90 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.